Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours.

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Asthma management often involves bronchodilators to alleviate bronchoconstriction.
• Understanding the duration of protection against specific stimuli is crucial for effective treatment.

Purpose of the Study:

• To investigate the dose-response relationship and duration of protection offered by salmeterol against isocapnic hyperventilation of cold air in asthmatic patients.
• To compare the efficacy of salmeterol with salbutamol in preventing exercise-induced bronchoconstriction.

Main Methods:

• A double-blind, randomized, cross-over study involving 16 asthmatic patients.
• Patients underwent isocapnic hyperventilation tests with cold air after inhaling salmeterol (50 mcg), salbutamol (200 mcg), or placebo.
• Forced expiratory volume in 1 second (FEV1) and provocative ventilation (PV20) were measured at various time points up to 12 hours post-inhalation.

Main Results:

• Salmeterol demonstrated a significant protective effect against bronchoconstriction for up to 12 hours, maintaining higher FEV1 values compared to placebo.
• Salbutamol showed a significant difference from placebo only up to 4 hours post-inhalation.
• The provocative ventilation required to induce a 20% fall in FEV1 (PV20FEV1) was significantly higher with salmeterol for up to 12 hours, indicating sustained protection.

Conclusions:

• Salmeterol offers prolonged protection against hyperventilation-induced bronchoconstriction in asthma patients, lasting at least 12 hours.
• This sustained protection extends beyond its immediate bronchodilating effects.
• Salmeterol's long-acting nature makes it a valuable option for managing asthma symptoms triggered by stimuli like cold air.